First slide
Sureseq Logo

Product summary

  • Technology NGS
  • Application Hematology
  • Areas of interest Myeloid, AML, MDS, MPN
  • Panel Size 11.2 kb
  • Gene Targets 45 hotspot exons from 13 genes
  • Mean target coverage Up to 20,000x
  • Product Code 780126-48
  • Regulatory Status For research use only; not for diagnostic procedures.



Measurable residual disease (MRD) — the presence of cancerous cells below the threshold of detection of conventional morphologic methods — is routinely investigated post treatment to research the risk of relapse and to explore potential therapeutic strategies.

Several methodologies are currently used to assess MRD in acute myeloid leukemia (AML), including immunophenotypic multiparameter flow cytometry (MFC), real-time quantitative polymerase chain reaction (RT-PCR), digital droplet PCR (ddPCR) and next-generation sequencing (NGS).

MFC provides valuable information about antigen expression implicated in MRD but does not assess genetic biomarkers, while PCR-based techniques are highly sensitive but are limited by the number of targets that can be detected simultaneously.

In contrast next-generation sequencing (NGS) offers highly sensitive and specific analysis of multiple AML-associated genes, allowing comprehensive MRD analysis of a wide-range of AML subtypes, including the identification of sample-specific mutations.

  • Designed in collaboration with leading cancer experts: Detect SNVs and indels in 45 hotspot exons across 13 genes associated with accurate MRD detection in AML samples — including MDS and MPN implicated genes
  • Class-leading sensitivity: Designed to detect low-frequency variants down to 0.05% VAF with confidence, even in challenging genes such as NPM1, CEBPA and FLT3-ITD
  • Rapid and cost-efficient: Simultaneously assay multiple targets with a single NGS panel in a streamlined workflow
  • Complimentary data analysis software: Powerful and intuitive Interpret NGS Analysis Software for confident variant calling, including longitudinal monitoring

Gene targets

Select a gene to view exon coverage examples:

* Exon examples not yet available


Expert-led, evidence-based content

The SureSeq™ Myeloid MRD Panel has been designed in collaboration with leading cancer experts and in accordance with the European LeukemiaNet (ELN) recommendations1 to offer a single, cost-effective NGS assay to investigate MRD in AML samples. The panel content incorporates key genes for assessing AML, including genes implicated in MPN and MDS to investigate secondary AML progression.

In addition, genes related to research on potential drug response are included, for truly comprehensive and informative sample analysis.

Utilizing OGT’s intelligent panel design capabilities, the SureSeq Myeloid MRD Panel surpasses the typical sensitivities offered by alternative NGS panels to accurately detect SNVs, indels and internal tandem duplications (ITDs) down to 0.05% VAF.

Unparalleled uniformity and depth of coverage

NPM1 is the most commonly mutated gene in adult AML, present in approximately 25-35% of cases2, making it an essential marker for MRD monitoring. NPM1 mutations occur almost exclusively in exon 11; a difficult region to sequence due to multiple perfectly matched copies replicated across the genome. The sophisticated bait design used in the SureSeq Myeloid MRD Panel overcomes this issue to deliver exceptional coverage uniformity, enabling reliable detection of all target regions (Figure 1).

FLT3 internal tandem duplications (ITDs) are present in approximately 25% of AML cases and are an important negative prognostic marker3; however, their inherent repeat content and length (up to 300 bp4) make them challenging to target, and subsequently detect. As a result, they are masked in many gene panels, necessitating additional techniques to characterize these important mutations. The unique detection algorithms incorporated into the complimentary Interpret NGS Analysis Software enable accurate detection and quantification of FLT3-ITDs, including multiple and large ITDs (Figure 2).

Combining coverage uniformity with a focused, expert-led panel design allows greater sequencing depth, which further enhances sensitivity at lower sequencing cost. SNVs, indels and ITDs across all targeted genes and regions can be detected down to 0.05% VAF (Table 2).

Rapid, streamlined workflow

All SureSeq NGS panels combine the superior performance of hybridization-based enrichment with the streamlined and automatable Universal NGS Complete Workflow Solution to deliver unparalleled results with minimal hands-on time (Figure 3). The incorporation of Unique Molecular Identifiers (UMIs) and Unique Dual Indexes (UDIs) prior to sample amplification, allows true variants to be distinguished from PCR artefacts, for highly sensitive and reliable results.

Complimentary data analysis software

OGT’s powerful and easy-to-use Interpret NGS Analysis Software facilitates analysis and visualization of a wide range of somatic variants including structural aberrations.

Designed to work seamlessly with all SureSeq NGS panels, the software delivers fast and accurate detection of all SNVs, indels and ITDs. Following detection, all variants are displayed in the user-friendly variant browser, for effortless translation of all your myeloid MRD data into meaningful results. The reporting tool also enables visualization of changing MRD dynamics over time (Figure 4).

The software can be deployed locally or in the cloud to suit your analysis infrastructure.

Our range of innovative NGS myeloid malignancy solutions

Browse our full range of myeloid panels, including the focused three-gene SureSeq Core MPN Panel and the SureSeq Pan-Myeloid Panel, incorporating key variants in 70 genes implicated in a wide range of myeloid disorders. In addition, the RNA-based SureSeq Myeloid Fusion Panel enables detection of 30 common fusions and novel fusion partners for key myeloid cancer genes.

SureSeq Myeloid MRD NGS Panel workflow

Content selection Image

Content selection

Sure Seq Bar 1
  • SureSeq Myeloid MRD NGS Panel
Sequencing Image


Sure Seq Bar 3
  • Illumina sequencers

What our customers say


  1. European LeukaemiaNET. Available at:
  2. Hindley et al., Int J Mol Sci 2021; 22(18):10040.
  3. Daver et al., Leukemia 2019; 33: 299-312.
  4. Spencer et al., J Mol Diagn 2013; 15(1):81-93.

Request a quote for this product

NGS resources & support